Legacy Healthcare
William-F Pralong is the Chief Scientific Officer at Legacy Healthcare and an Emeritus Professor at Ecole polytechnique fédérale de Lausanne. William-F has extensive experience in the development of educational programs in Life Sciences and Technology, Bioengineering, and the School of Life Sciences. Additionally, William-F has served in various roles such as Vice-President of the Ethical Comity for the Research on the Human Being at Etat de Vaud and as a Member of the Council at Conseil suisse d’accréditation/Akkreditierungsrat. Their research background includes work on Diabetic Neuropathy and Molecular Physiology of Pancreatic Islet Cells.
This person is not in any teams
Legacy Healthcare
Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile population, e.g. children, cancer patients and the elderly, who may be already on multiple medications. Our first drug, Coacillium, is currently in Phase II/III testing for the treatment of Alopecia Areata, a debilitating scalp condition with intense medical and psychological impact on all patients, especially in children, and their families. Coacillium’s safety profile is without equal. For this reason health authorities have taken the unusual step of authorizing testing in children (starting at age 2) before adult testing. We expect Coacillium to be approved by 2023, as the first drug for Pediatric Alopecia Areata.